Carbapenem is an important therapy for serious hospital‐acquired infections and for the
care of patients affected by multidrug‐resistant organisms, specifically Acinetobacter …

Carbapenem resistance is a major global health problem that seriously compromises the
treatment of infections caused by nosocomial pathogens. Resistance to carbapenems …

Background An urgent need exists for antibiotics to treat infections caused by carbapenem-
resistant Acinetobacter baumannii–calcoaceticus complex (ABC). Sulbactam–durlobactam …

Sulbactam-durlobactam is a β-lactam-β-lactamase inhibitor combination designed to treat
serious Acinetobacter baumannii-calcoaceticus complex (ABC) infections, including …

Durlobactam is a new member of the diazabicyclooctane class of β-lactamase inhibitors with
broad spectrum activity against Ambler class A, C, and D serine β-lactamases. Sulbactam is …

This review critically appraises the published microbiologic and clinical data on the
treatment of patients with carbapenem‐resistant Acinetobacter baumannii infections …

Abstract Sulbactam/durlobactam (XACDURO®), is a co-packaged antibacterial product that
has been developed by Entasis Therapeutics Inc. for the treatment of infections caused by …

Background Acinetobacter baumannii is a leading cause of healthcare-associated infections
worldwide, due to both its persistence in the hospital setting and ability to acquire high levels …

Sulbactam-durlobactam is a pathogen-targeted β-lactam/β-lactamase inhibitor combination
in late-stage development for the treatment of Acinetobacter infections, including those …

Carbapenem‐resistant Acinetobacter baumannii (CRAB) is a difficult‐to‐treat nosocomial
pathogen responsible for significant morbidity and mortality. Sulbactam‐durlobactam (SUL …